The unraveling of relations between the United States and India has convinced many Indian officials that the country should return to its difficult balancing act of nonalignment.

U.S. President Donald Trump has identified India, Pakistan, China, and Afghanistan as major drug transit or illicit drug-producing countries, warning that their narcotics production threatens U.S. safety.

On August 27, President Donald Trump’s 50 percent tariffs on India, some of the steepest he has imposed on any country in the world, went into effect. The levies mark an astounding rupture between the world’s two largest democracies—and a setback for a partnership whose geopolitical significance had been growing.

Rising imbalances in trade, tariff asymmetries, and intellectual property disputes are reshaping one of the world's most important economic partnerships.

Military-to-military engagements that advance both capacity building and capability enhancement between India and the United States are quietly continuing.

India must decide whether to go all in with a capricious Trump or hedge its bets through a rapprochement with China.

A new strategic alliance between the United States and India would be established by a treaty subject to advice and consent by the U.S. Senate. It would be built on five core pillars, with the aim of enhancing the mutual security, prosperity, and values of both countries.

Weakening America-India ties are not only a diplomatic error, they will likely prevent the country from doing well in the event of a new war.

US President Donald Trump has named 23 countries as the major drug transit or major illicit drug-producing countries in a 'Presidential Determination' submitted to Congress.

The rupee appreciated 25 paise to close at 87.84 (provisional) against US dollar on Wednesday, tracking a positive trend in domestic equities and supported by optimism over US–India trade negotiations.